Compare STG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | PRLD |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.1M | 529.1M |
| IPO Year | 2017 | 2020 |
| Metric | STG | PRLD |
|---|---|---|
| Price | $2.92 | $3.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 6.7K | ★ 447.7K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $2.44 | $1.15 |
| 52 Week High | $8.53 | $6.83 |
| Indicator | STG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 31.54 |
| Support Level | $2.82 | $3.40 |
| Resistance Level | $3.62 | $4.10 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 59.96 | 2.15 |
Sunlands Technology Group operates in China's adult online education market and adult personal interest learning market through its online platforms. The Group has a deep understanding of the educational needs of its prospective students and offers solutions to help them achieve their goals. It provides online professional courses and educational content, including interest, professional skills, professional certification preparation courses, and degree- or diploma-oriented post-secondary courses. The Group adopts a counseling-oriented sales and marketing approach to offer education solutions based on students' backgrounds and goals, delivering adult online education and personal interest learning through extensive course and content offerings.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.